{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-287172","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.692359+00:00","generated_at":"2026-05-28T21:57:38.379508+00:00","sec_items":["1.01","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Royalty Pharma amends exchange agreement for internal EPA holdings restructuring","bullets":["Amended Exchange Agreement transfers Holdings C Share from RPI EPA Holdings to RPI EPA Vehicle.","Articles of association of Royalty Pharma Holdings Limited amended and restated.","Restructuring involves equity performance awards (EPA) entity substitution.","No changes to publicly traded Royalty Pharma plc's operations or financials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-287172","json":"https://secwatch.observer/filing/0001193125-24-287172.json","markdown":"https://secwatch.observer/filing/0001193125-24-287172.md","text":"https://secwatch.observer/filing/0001193125-24-287172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524287172/0001193125-24-287172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524287172/d900232d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T21:57:38.379508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}